Clinical Edge Journal Scan

Risk factors for osteoporosis in CHF patients


 

Key clinical point: Use of loop diuretics and nonuse of direct oral anticoagulants (DOACs) were independently associated with an increased risk of osteoporosis in patients with chronic heart failure (CHF).

Major finding: Use of loop diuretics (odds ratio [OR], 2.70; P less than .01) and nonuse of DOACs (OR for DOAC use, 0.36; P = .01) were associated with an increased risk for osteoporosis . Patients with osteoporotic BMD at 2 or 3 sites had a significantly higher rate of a composite of death and heart failure hospitalization than patients without osteoporosis (hazard ratio, 3.45; P less than .01).

Study details: The data come from a single-center, retrospective study of 303 (osteoporosis: n = 122; nonosteoporosis: n = 181) patients diagnosed with CHF.

Disclosures: The study was supported by a Grant-in-Aid for Young Scientists (S Katano) from the Japan Society for the Promotion of Science, KAKENHI, Tokyo, Japan. The authors reported no conflicts of interest. Dr. T Miura is a member of the Circulation Journal’s editorial team.

Source: Katano S et al. Circ J. 2020 Oct 28. doi: 10.1253/circj.CJ-20-0593 .

Recommended Reading

Teenage bone density declines following sleeve gastrectomy
MDedge Rheumatology
Zoledronic acid treatment for osteoporosis modestly raises AFib risk
MDedge Rheumatology
BMD and bone turnover after gastric bypass vs. sleeve gastrectomy
MDedge Rheumatology
Corticosteroids for asthma could raise osteoporosis and fragility fracture risk
MDedge Rheumatology
Denosumab not linked to malignancy risk in patients with osteoporosis
MDedge Rheumatology
Efficacy of romosozumab followed by denosumab in women at high risk of fracture
MDedge Rheumatology
Psoriasis tied to increased risk for osteoporosis
MDedge Rheumatology
Protective action of impaired fasting glucose on osteoporosis risk
MDedge Rheumatology
Higher prevalence of periapical lesions in patients with osteoporosis
MDedge Rheumatology
Switching to denosumab prevents osteoporosis progression in postmenopausal women with T2D
MDedge Rheumatology